Castle Biosciences, Inc.

NASDAQ:CSTL

Medical - Diagnostics & Research

Healthcare
$33.38 +0.20%

+$0.04 today

Market cap
$1.03B
Beta
1.02
P/E (TTM)
-47.3
EPS (TTM)
-$0.43
52W Low $14.59High $44.28

Volume 0.38M

Average 0.37M

CSTL Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Castle Biosciences, Inc.NASDAQ: CSTL

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $14.43M rose 14.6% year over year, ahead of the +5.8% change in trailing-twelve-month research & development. Sequentially, it rose 6.8% from the prior quarter. Over 3 fiscal years it compounded at +4.9% a year.

Context

  • Research & development amounted to 15.1% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +14.6% holds above the trailing-twelve-month pace of +5.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.43M+6.8% QoQ
Last fiscal yearDec 2025
$51.85M-0.4% YoY
LTMMar 2026
$53.69M+5.8% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.6%——
1 year-0.4%——
3-year CAGR+4.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
51.85M USD
Year-over-year change
-0.4%
4-year CAGR
+15.0%

Research & Development vs competitors

How CSTL compares with its peers on the latest reported figures

  • CSTL's LTM Mar 2026 research & development of $53.69M is the 4th highest of the 8 companies compared; the peer median is $52.16M.
  • Its year-over-year change of +5.8% is the 6th highest of 8, against a peer median of +7.6%.
  • Research & development amounts to 15.8% of revenue for CSTL, versus a peer median of 12.9%.
CSTL Competitors Peer median
Research & Development for CSTL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GHGuardant Health, Inc.LTM Sep 2026$386.67M +7.6%-0.9%30.2%
MYGNMyriad Genetics, Inc.LTM Mar 2026$106.4M -7.7%+7.7%12.8%
VCYTVeracyte, Inc.LTM Jun 2026$93.37M +31.8%+20.4%16.6%
CSTLCastle Biosciences, Inc.LTM Mar 2026$53.69M +5.8%+4.9%15.8%
PSNLPersonalis, Inc.LTM Mar 2026$52.16M +6.9%-8.2%80.9%
NEONeoGenomics, Inc.LTM Jun 2026$38.17M +9.5%+6.9%5.0%
BDSXBiodesix, Inc.LTM Mar 2026$12.42M +19.5%-2.9%12.9%
MDXHMDxHealth S.A.FY2025$10.35M -1.9%+11.1%9.6%
FRNMFreenome, Inc. Common stock—— ———
Peer median (excluding CSTL) $52.16M+7.6%+6.9%12.9%

Competitors are the stored peer set for CSTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue94.09M137.04M219.79M332.07M344.23M
Cost of Revenue15.82M32.01M44.98M60.21M71.03M
Gross Profit78.26M105.03M174.81M271.86M273.2M
Gross Margin83.2%76.6%79.5%81.9%79.4%
Research & Development29.65M44.9M53.62M52.04M51.85M
Selling, General & Admin86.74M143M180.15M200.05M229.32M
Operating Expenses118.34M177.89M242.78M263.19M316.01M
Depreciation & Amortization3.41M10.54M12.33M16M40.77M
EBITDA(36.6M)(58.34M)(45.02M)38.14M11.34M
EBITDA Margin-38.9%-42.6%-20.5%11.5%3.3%
Operating Income(40.08M)(72.86M)(67.98M)8.67M(42.81M)
Operating Margin-42.6%-53.2%-30.9%2.6%-12.4%
Interest Income68K3.97M10.62M12.92M11.77M
Interest Expense1K17K11K577K86K
Other Income / Expenses67K3.95M10.61M12.89M13.3M
Income Before Tax(40.01M)(68.9M)(57.37M)21.56M(29.51M)
Pre-Tax Margin-42.5%-50.3%-26.1%6.5%-8.6%
Income Tax Expense(8.72M)(1.77M)101K3.32M(5.36M)
Net Income(31.29M)(67.14M)(57.47M)18.25M(24.16M)
Net Margin-33.3%-49.0%-26.1%5.5%-7.0%
EPS (Basic)(1.24)(2.58)(2.14)0.66(0.83)
EPS (Diluted)(1.24)(2.58)(2.14)0.62(0.83)
Weighted Avg Shares25.14M26.05M26.8M27.78M28.99M
Weighted Avg Shares (Diluted)25.14M26.05M26.8M29.26M28.99M

Castle Biosciences, Inc.

NASDAQ:CSTL

Intrinsic Alpha fair value

Locked

Current Price

$33.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.